Amalia Douma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amalia Douma has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Kassiani Theodoraki
Department of Anesthesiology, Aretaieion University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
3 shared publications - Panagiotis Chatzistavridis
Department of Anesthesiology, General Hospital of Athens “G. Gennimatas”, 115 27 Athens, Greece
3 shared publications - Anna Gkiouliava
Department of Anaesthesiology and Intensive Care, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital, 54636 Thessaloniki, Greece
2 shared publications - Antigoni Malefaki1 shared publication
- Antonia Andreeva1 shared publication
- Antonia Dimakopoulou1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 721
The Predictive Value of Simple Inflammatory and Nutritional Indices for Postoperative Complications in Bariatric Surgery Patients: A Study Protocol for a Single-Centre Retrospective Study from a Referral Hospital
Background/Objectives: Nutritional depletion and systemic inflammation are common in patients living with obesity undergoing metabolic bariatric surgery (MBS) and may influence the risk of early postoperative complications. Composite indices derived from routine blood tests—combining markers of protein/immune reserve and inflammatory burden—offer an inexpensive means of preoperative risk stratification, but their comparative performance in MBS has not been well defined. The primary objective is to compare the prognostic performance of seven preoperative indices for early postoperative complications after MBS; the secondary objective is to estimate and rank the incremental prognostic value of each index over baseline clinical risk factors. Methods: This protocol describes a single-centre retrospective cohort study of approximately 700 consecutive adults who underwent sleeve gastrectomy, one-anastomosis gastric bypass, Roux-en-Y gastric bypass, single-anastomosis duodeno-ileal bypass with sleeve gastrectomy or single-anastomosis sleeve-ileal bypass, including revisional procedures, between 1 January 2023 and 28 June 2026; data extraction will begin only after submission of this protocol. The Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), C-reactive protein-to-Albumin Ratio (CAR) and Glucose-to-Lymphocyte Ratio (GLR) will be calculated from complete blood count, albumin, C-reactive protein and fasting glucose values. The last preoperative sample is the exposure; early postoperative values (postoperative days 1–3) will be examined in a separate exploratory landmark analysis. The primary outcome is any complication of Clavien–Dindo grade II or higher within 30 days of surgery; readmission within 30 days of surgery and prolonged hospital stay will be analysed as secondary healthcare-utilisation outcomes. The indices will be compared by their optimism-corrected incremental discrimination over a baseline clinical model, using penalised logistic regression with bootstrap internal validation and calibration assessment. Conclusions: This protocol outlines a pragmatic approach to comparing seven low-cost, routinely available nutritional–inflammatory and inflammatory indices for risk stratification before MBS. Indices showing promising performance will require external, ideally multicentre, validation before they can be considered for clinical decision making.
- 27 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 721
Open AccessThe Predictive Value of Simple Inflammatory and Nutritional Indices for Postoperative Complications in Bariatric Surgery Patients: A Study Protocol for a Single-Centre Retrospective Study from a Referral Hospital
Background/Objectives: Nutritional depletion and systemic inflammation are common in patients living with obesity undergoing metabolic bariatric surgery (MBS) and may influence the risk of early postoperative complications. Composite indices derived from routine blood tests—combining markers of protein/immune reserve and inflammatory burden—offer an inexpensive means of preoperative risk stratification, but their comparative performance in MBS has not been well defined. The primary objective is to compare the prognostic performance of seven preoperative indices for early postoperative complications after MBS; the secondary objective is to estimate and rank the incremental prognostic value of each index over baseline clinical risk factors. Methods: This protocol describes a single-centre retrospective cohort study of approximately 700 consecutive adults who underwent sleeve gastrectomy, one-anastomosis gastric bypass, Roux-en-Y gastric bypass, single-anastomosis duodeno-ileal bypass with sleeve gastrectomy or single-anastomosis sleeve-ileal bypass, including revisional procedures, between 1 January 2023 and 28 June 2026; data extraction will begin only after submission of this protocol. The Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), C-reactive protein-to-Albumin Ratio (CAR) and Glucose-to-Lymphocyte Ratio (GLR) will be calculated from complete blood count, albumin, C-reactive protein and fasting glucose values. The last preoperative sample is the exposure; early postoperative values (postoperative days 1–3) will be examined in a separate exploratory landmark analysis. The primary outcome is any complication of Clavien–Dindo grade II or higher within 30 days of surgery; readmission within 30 days of surgery and prolonged hospital stay will be analysed as secondary healthcare-utilisation outcomes. The indices will be compared by their optimism-corrected incremental discrimination over a baseline clinical model, using penalised logistic regression with bootstrap internal validation and calibration assessment. Conclusions: This protocol outlines a pragmatic approach to comparing seven low-cost, routinely available nutritional–inflammatory and inflammatory indices for risk stratification before MBS. Indices showing promising performance will require external, ideally multicentre, validation before they can be considered for clinical decision making.
- Open Access
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8300
Propofol Target-Controlled Infusion with the Eleveld Model in Opioid-Sparing and Opioid-Free Anaesthesia: A Narrative Review
Background/Objectives: The Eleveld pharmacokinetic–pharmacodynamic (PK-PD) model is among the most extensively validated general-purpose models for propofol target-controlled infusion (TCI). It includes a binary covariate for concomitant drug administration, commonly labelled as opioid use, which reduces elimination clearance (CL) and the volume of the second peripheral compartment (V3) in an age-dependent manner. This works well for conventional opioid-based anaesthesia but is less clear for multimodal, opioid-sparing regimens built around ketamine, magnesium sulfate, dexmedetomidine and intravenous lidocaine. This review discusses how these four non-opioid adjuvants may interact with Eleveld-based propofol TCI dosing. Methods: We conducted a structured, non-systematic literature search of PubMed/MEDLINE, the Cochrane Library and the MDPI full-text index between May and early August 2026, combining terms for the Eleveld model and propofol TCI with terms for each adjuvant and for pharmacodynamic endpoints (EC50, Ce50, bispectral index, propofol requirement). Studies without a propofol-specific endpoint were excluded from the adjuvant-effect analysis. Results: Dexmedetomidine reduced the propofol concentration required for defined clinical and electroencephalographic endpoints. Magnesium sulfate reduced propofol dose requirements to a lesser extent, although concentration–response data are lacking. Ketamine’s interaction with propofol was additive rather than synergistic, and its effect on the bispectral index was dose-dependent. Lidocaine reduced propofol requirements mainly during surgical stimulation, a context-dependent effect distinct from a fixed hypnotic potency. Conclusions: The Eleveld model remains the best-validated general-purpose tool for propofol TCI, and its concomitant-drug covariate is a pragmatic, data-driven solution to a real gap in its source data. Clinicians should anticipate reduced propofol requirements with dexmedetomidine and, to a lesser extent, magnesium, interpret the processed-EEG response to ketamine cautiously, and expect lidocaine’s sparing effect mainly under stimulation, while titrating to clinical and electroencephalographic endpoints. Dedicated covariates for these agents, informed by prospective validation in opioid-free regimens, represent a logical next step in the model’s development.
- 25 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8300
Open AccessPropofol Target-Controlled Infusion with the Eleveld Model in Opioid-Sparing and Opioid-Free Anaesthesia: A Narrative Review
Background/Objectives: The Eleveld pharmacokinetic–pharmacodynamic (PK-PD) model is among the most extensively validated general-purpose models for propofol target-controlled infusion (TCI). It includes a binary covariate for concomitant drug administration, commonly labelled as opioid use, which reduces elimination clearance (CL) and the volume of the second peripheral compartment (V3) in an age-dependent manner. This works well for conventional opioid-based anaesthesia but is less clear for multimodal, opioid-sparing regimens built around ketamine, magnesium sulfate, dexmedetomidine and intravenous lidocaine. This review discusses how these four non-opioid adjuvants may interact with Eleveld-based propofol TCI dosing. Methods: We conducted a structured, non-systematic literature search of PubMed/MEDLINE, the Cochrane Library and the MDPI full-text index between May and early August 2026, combining terms for the Eleveld model and propofol TCI with terms for each adjuvant and for pharmacodynamic endpoints (EC50, Ce50, bispectral index, propofol requirement). Studies without a propofol-specific endpoint were excluded from the adjuvant-effect analysis. Results: Dexmedetomidine reduced the propofol concentration required for defined clinical and electroencephalographic endpoints. Magnesium sulfate reduced propofol dose requirements to a lesser extent, although concentration–response data are lacking. Ketamine’s interaction with propofol was additive rather than synergistic, and its effect on the bispectral index was dose-dependent. Lidocaine reduced propofol requirements mainly during surgical stimulation, a context-dependent effect distinct from a fixed hypnotic potency. Conclusions: The Eleveld model remains the best-validated general-purpose tool for propofol TCI, and its concomitant-drug covariate is a pragmatic, data-driven solution to a real gap in its source data. Clinicians should anticipate reduced propofol requirements with dexmedetomidine and, to a lesser extent, magnesium, interpret the processed-EEG response to ketamine cautiously, and expect lidocaine’s sparing effect mainly under stimulation, while titrating to clinical and electroencephalographic endpoints. Dedicated covariates for these agents, informed by prospective validation in opioid-free regimens, represent a logical next step in the model’s development.
- Open Access
- 23 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 698
Safety of Target-Controlled Infusion in Patients with Obesity: A Narrative Review
Background/Objectives: Obesity alters propofol pharmacokinetics, creating bidirectional safety concerns during Target-Controlled Infusion (TCI). The 5th National Audit Project reported that patients with obesity were over-represented among cases of accidental awareness, and that awareness was more frequent when neuromuscular blockade was used. Methods: We examined the literature on the mechanisms and clinical evidence underlying relative overdosing, underdosing, awareness, and postoperative respiratory risk in patients with obesity receiving propofol anesthesia. Results: Total body-weight dosing may produce an excessive initial concentration, because the central compartment expands less than body weight, contributing to hemodynamic instability at induction. Conversely, inappropriate dose reduction based on lean or ideal body weight may result in inadequate anesthetic depth. Risk reduction requires the best-validated pharmacokinetic model or weight-adjustment method available, stepwise titration of the target concentration, processed electroencephalographic monitoring when total intravenous anesthesia is combined with neuromuscular blockade, quantitative neuromuscular monitoring, delivery-system checks, and vigilant postoperative respiratory monitoring. Closed-loop delivery may improve control of anesthetic depth, but a reduction in serious adverse events has not been demonstrated. Conclusions: Evidence remains limited at the upper extremes of body mass index; model predictions and fixed weight scalars should be interpreted cautiously, and dosing should be individualized using measured pharmacodynamic endpoints.
- 23 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 698
Open AccessSafety of Target-Controlled Infusion in Patients with Obesity: A Narrative Review
Background/Objectives: Obesity alters propofol pharmacokinetics, creating bidirectional safety concerns during Target-Controlled Infusion (TCI). The 5th National Audit Project reported that patients with obesity were over-represented among cases of accidental awareness, and that awareness was more frequent when neuromuscular blockade was used. Methods: We examined the literature on the mechanisms and clinical evidence underlying relative overdosing, underdosing, awareness, and postoperative respiratory risk in patients with obesity receiving propofol anesthesia. Results: Total body-weight dosing may produce an excessive initial concentration, because the central compartment expands less than body weight, contributing to hemodynamic instability at induction. Conversely, inappropriate dose reduction based on lean or ideal body weight may result in inadequate anesthetic depth. Risk reduction requires the best-validated pharmacokinetic model or weight-adjustment method available, stepwise titration of the target concentration, processed electroencephalographic monitoring when total intravenous anesthesia is combined with neuromuscular blockade, quantitative neuromuscular monitoring, delivery-system checks, and vigilant postoperative respiratory monitoring. Closed-loop delivery may improve control of anesthetic depth, but a reduction in serious adverse events has not been demonstrated. Conclusions: Evidence remains limited at the upper extremes of body mass index; model predictions and fixed weight scalars should be interpreted cautiously, and dosing should be individualized using measured pharmacodynamic endpoints.
- 2 September 2019
- Published by Morressier GmbH
OPIOID FREE ANAESTHESIA AND ANALGESIA IN A PATIENT WITH OPIOID ALLERGY
- 2 September 2019
- Published by Morressier GmbH
OPIOID FREE ANAESTHESIA AND ANALGESIA IN A PATIENT WITH OPIOID ALLERGY